Rare disease drug maker Ultragenyx plans to hire 100-150 at new gene therapy facility near Boston

Potential one-shot-and-cured gene therapy programs are increasing in clinical trials, putting pressure on third-party contract manufacturing organizations and the companies that use them.

Click to view original post